Based on the frequent coexpression of ICRs in tumor tissues and the distinct yet convergent mechanisms of action (Table 1), it is expected that combined blockade of these emerging ICRs with PD-L1/PD-1 will result in additive or synergistic outcomes. This evidence concerns the gene CD274 and neoplasm.